ZA200809002B - Cycloalkylamino acid derivatives and pharmaceutical compositions thereof - Google Patents

Cycloalkylamino acid derivatives and pharmaceutical compositions thereof

Info

Publication number
ZA200809002B
ZA200809002B ZA200809002A ZA200809002A ZA200809002B ZA 200809002 B ZA200809002 B ZA 200809002B ZA 200809002 A ZA200809002 A ZA 200809002A ZA 200809002 A ZA200809002 A ZA 200809002A ZA 200809002 B ZA200809002 B ZA 200809002B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical compositions
acid derivatives
cycloalkylamino acid
cycloalkylamino
derivatives
Prior art date
Application number
ZA200809002A
Other languages
English (en)
Inventor
Samit Kumar Bhattacharya
Matthew Frank Brown
Peter Hans Dorff
Susan Lagreca
Robert John Maguire
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200809002B publication Critical patent/ZA200809002B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
ZA200809002A 2006-05-09 2008-10-21 Cycloalkylamino acid derivatives and pharmaceutical compositions thereof ZA200809002B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79921106P 2006-05-09 2006-05-09

Publications (1)

Publication Number Publication Date
ZA200809002B true ZA200809002B (en) 2009-12-30

Family

ID=38420744

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200809002A ZA200809002B (en) 2006-05-09 2008-10-21 Cycloalkylamino acid derivatives and pharmaceutical compositions thereof

Country Status (27)

Country Link
US (2) US7671043B2 (es)
EP (2) EP2021338A1 (es)
JP (1) JP4383525B2 (es)
KR (1) KR20090007792A (es)
CN (1) CN101490046A (es)
AR (1) AR061083A1 (es)
AU (1) AU2007251282A1 (es)
BR (1) BRPI0711358A2 (es)
CA (1) CA2651629A1 (es)
CR (1) CR10412A (es)
DO (1) DOP2007000092A (es)
EA (1) EA200802058A1 (es)
EC (1) ECSP088870A (es)
IL (1) IL194954A0 (es)
MA (1) MA30403B1 (es)
ME (1) MEP43308A (es)
MX (1) MX2008013990A (es)
NL (1) NL2000627C2 (es)
NO (1) NO20084382L (es)
PE (1) PE20080091A1 (es)
RS (1) RS20080525A (es)
TN (1) TNSN08446A1 (es)
TW (1) TW200808783A (es)
UA (1) UA91129C2 (es)
UY (1) UY30326A1 (es)
WO (1) WO2007132307A1 (es)
ZA (1) ZA200809002B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007132307A1 (en) * 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
ES2400533T3 (es) 2006-09-07 2013-04-10 Actelion Pharmaceuticals Ltd. Derivados de piridin 4-ilo como agentes inmunomoduladores
RU2454413C2 (ru) 2006-09-08 2012-06-27 Актелион Фармасьютиклз Лтд Производные пиридин-3-ила в качестве иммуномодулирующих агентов
US8044076B2 (en) 2006-09-21 2011-10-25 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
US7834039B2 (en) 2006-12-15 2010-11-16 Abbott Laboratories Oxadiazole compounds
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
SI2125797T1 (sl) 2007-03-16 2014-03-31 Actelion Pharmaceuticals Ltd. Derivati amino-piridina kot agonisti receptorja s1p1/edg1
GB0706633D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd Combination
EP2209771A1 (en) * 2007-11-08 2010-07-28 Pfizer, Inc. Cyclobutyl carboxylic acid derivatives
KR20100110834A (ko) * 2007-12-21 2010-10-13 메르크 세로노 에스. 에이. 트리아졸 옥사다이아졸 유도체
US20110046170A1 (en) * 2008-03-06 2011-02-24 Martin Bolli Novel pyrimidine-pyridine derivatives
US20110028448A1 (en) * 2008-03-06 2011-02-03 Martin Bolli Pyridine compounds
WO2009109904A1 (en) 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
AU2009220861B2 (en) * 2008-03-07 2014-05-29 Idorsia Pharmaceuticals Ltd Pyridin-2-YL derivatives as immunomodulating agents
WO2009131090A1 (ja) * 2008-04-21 2009-10-29 旭化成ファーマ株式会社 アミノ酸化合物
KR20190132565A (ko) 2008-07-23 2019-11-27 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
CN105816453B (zh) 2008-08-27 2021-03-05 艾尼纳制药公司 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物
CA2752804C (en) * 2009-03-03 2017-04-04 Anna Quattropani Oxazole pyridine derivatives useful as s1p1 receptor agonists
BR112012000763B8 (pt) 2009-07-16 2021-05-25 Actelion Pharmaceuticals Ltd compostos derivados de piridin-4-il, composição farmacêutica, e, usos de um composto
TW201120016A (en) * 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
ES2937386T3 (es) 2010-01-27 2023-03-28 Arena Pharm Inc Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo
CA2789480A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
JP5869579B2 (ja) * 2010-09-24 2016-02-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用
AR084883A1 (es) 2011-01-19 2013-07-10 Actelion Pharmaceuticals Ltd Derivados de 2-metoxi-piridin-4-ilo
EP2511275A1 (en) 2011-04-12 2012-10-17 Bioprojet Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
DE102011083271A1 (de) 2011-09-23 2013-03-28 Beiersdorf Ag Aromatische Amidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Aromatischen Amidothiazolen
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
WO2016112075A1 (en) 2015-01-06 2016-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
EA035133B1 (ru) 2015-05-20 2020-04-30 Идорсия Фармасьютиклз Лтд Кристаллическая форма соединения (s)-3-{4-[5-(2-циклопентил-6-метоксипиридин-4-ил)-[1,2,4]оксадиазол-3-ил]-2-этил-6-метилфенокси}пропан-1,2-диола
SI3310760T1 (sl) 2015-06-22 2023-02-28 Arena Pharmaceuticals, Inc. Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1
AU2018222747A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CN109956912B (zh) * 2017-12-26 2021-10-22 中国医学科学院药物研究所 含二苯基噁二唑的羧酸类化合物、其制备方法及医药用途
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN112955431A (zh) 2018-09-06 2021-06-11 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
USD937488S1 (en) 2020-10-05 2021-11-30 Jonathan R. Barnes Pair of nail clipper handles

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
ATE134624T1 (de) 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5608082A (en) 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
US6071935A (en) 1996-06-27 2000-06-06 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
JP4386967B2 (ja) 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
WO1998002437A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
WO1999017770A1 (en) 1997-10-06 1999-04-15 Basf Aktiengesellschaft Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity
EA005889B1 (ru) 1997-11-11 2005-06-30 Пфайзер Продактс Инк. Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ATE270549T1 (de) 1998-04-30 2004-07-15 Abbott Gmbh & Co Kg Substituierte trizyklische pyrazolderivate mit protein kinase aktivität
EP2020408B1 (en) 1998-05-29 2013-06-26 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitor
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
EA200100135A1 (ru) 1998-08-27 2001-08-27 Пфайзер Продактс Инк. Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов
HUP0200355A3 (en) 1998-09-18 2004-07-28 Abbott Gmbh & Co Kg 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
SK3842001A3 (en) 1998-09-18 2002-04-04 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors (revised)
BR9915132A (pt) 1998-11-06 2001-08-07 Basf Ag Método para inibir a atividade de quinase de proteìna, compostos da fórmula i e sais farmaceuticamente aceitáveis dos mesmos, uso do mesmo, e, composição farmacêutica.
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
TR200201296T2 (tr) 1999-02-11 2002-07-22 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
IL146474A0 (en) 1999-06-03 2002-07-25 Knoll Gmbh Benzothiazinone and benzoxazinone compounds
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
KR20020050294A (ko) 1999-11-22 2002-06-26 피터 기딩스 신규화합물
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
BRPI0108394B8 (pt) 2000-02-15 2021-05-25 Upjohn Co inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
CA2406685C (en) 2000-04-21 2006-10-31 Shionogi & Co., Ltd. Oxadiazole derivatives having anticancer effects
CA2413424C (en) 2000-06-22 2007-10-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
AU2002232439A1 (en) 2000-11-29 2002-06-11 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
ES2344592T3 (es) 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
JPWO2003020313A1 (ja) 2001-09-04 2004-12-16 小野薬品工業株式会社 スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤
US7427623B2 (en) 2001-09-11 2008-09-23 Smithkline Beecham Corporation 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
WO2003066601A1 (en) 2002-02-08 2003-08-14 Smithkline Beecham Corporation Pyrimidine compounds
DE60314500T2 (de) 2002-03-01 2008-02-07 Smithkline Beecham Corp. Diaminopyrimidine und deren verwendung als angiogenesehemmer
US20050215531A1 (en) 2002-05-16 2005-09-29 Thomas Baumruker Use of edg receptor binding agents in cancer
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
SE0203654D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab New compounds
JP2006522820A (ja) 2003-04-10 2006-10-05 アバニール・ファーマシューティカルズ アレルギーおよび過剰増殖疾患の治療のためのイミダゾール誘導体
US7071333B2 (en) 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
CA2547198A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
ATE433979T1 (de) 2004-04-02 2009-07-15 Osi Pharm Inc Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
RU2417993C9 (ru) * 2004-05-18 2011-10-10 Шеринг Корпорейшн Замещенные 2-хинолилоксазолы, пригодные в качестве ингибиторов фдэ4
WO2007132307A1 (en) * 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
EP2209771A1 (en) * 2007-11-08 2010-07-28 Pfizer, Inc. Cyclobutyl carboxylic acid derivatives
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
MEP43308A (en) 2011-02-10
ECSP088870A (es) 2008-12-30
JP2009536190A (ja) 2009-10-08
PE20080091A1 (es) 2008-02-14
EA200802058A1 (ru) 2009-06-30
MX2008013990A (es) 2009-01-29
NO20084382L (no) 2008-11-19
EP2021338A1 (en) 2009-02-11
UA91129C2 (ru) 2010-06-25
TNSN08446A1 (en) 2010-04-14
AR061083A1 (es) 2008-08-06
RS20080525A (en) 2009-09-08
CN101490046A (zh) 2009-07-22
TW200808783A (en) 2008-02-16
CA2651629A1 (en) 2007-11-22
NL2000627A1 (nl) 2007-11-12
MA30403B1 (fr) 2009-05-04
DOP2007000092A (es) 2007-12-31
IL194954A0 (en) 2009-08-03
US20100120794A1 (en) 2010-05-13
UY30326A1 (es) 2008-01-02
US20070270438A1 (en) 2007-11-22
KR20090007792A (ko) 2009-01-20
US7671043B2 (en) 2010-03-02
BRPI0711358A2 (pt) 2011-09-27
WO2007132307A1 (en) 2007-11-22
NL2000627C2 (nl) 2009-03-17
AU2007251282A1 (en) 2007-11-22
EP2258700A1 (en) 2010-12-08
JP4383525B2 (ja) 2009-12-16
CR10412A (es) 2008-11-28

Similar Documents

Publication Publication Date Title
IL194954A0 (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
AP2008004671A0 (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
IL250937A0 (en) Pharmaceutical preparations and kits containing sphingomyelinase acid
IL196169A0 (en) Bile acid derivatives and pharmaceutical compositions containing the same
IL194546A0 (en) Arylaminopyridine derivatives and pharmaceutical compositions containing them
PL1861387T3 (pl) Pochodne benzoimidazolu i ich kompozycje farmaceutyczne
IL194460A0 (en) Deazapurine derivatives and pharmaceutical compositions containing the same
IL190292A (en) History of pyridopyrimidinone and their pharmaceutical preparations
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
IL194176A0 (en) Pharmaceutical compositions
GB0713625D0 (en) Pharmaceutical compositions
EP2025337A4 (en) EXTERNAL PHARMACEUTICAL COMPOSITION
EP2005959A4 (en) EXTERNAL PHARMACEUTICAL COMPOSITION
EP2005958A4 (en) TOPICAL PHARMACEUTICAL COMPOSITION
IL199853A (en) Converged history of 5-Hydroxy-Admentil-2-Reindeer and Pharmaceutical Preparation containing them
EP2056835A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
HK1138732A1 (en) Pharmaceutical compositions
PT1861387E (pt) Derivados de benzimidazol e composições farmacêuticas dos mesmos
IL206594A (en) The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
GB0614586D0 (en) Pharmaceutical Formulation
IL193211A (en) Derivatives of Indzol-Troaril and pharmaceutical preparations containing them
IL189614A0 (en) Pharmaceutical compositions of telmisartan
EP2070919A4 (en) SPIROCHINONE COMPOUND AND PHARMACEUTICAL COMPOSITION
GB0614365D0 (en) Pharmaceutical compositions and their use
PT2474528E (pt) Compostos antineoplásicos e composições farmacêuticas dos mesmos